Rhythm Pharmaceuticals (RYTM) Cash & Current Investments (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Cash & Current Investments of $340.6 million for Q1 2026, up 8.31% year-over-year from $314.5 million in Q1 2025, and down 12.42% quarter-over-quarter from $388.9 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Cash & Current Investments (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Cash & Current Investments for 11 consecutive years, with $340.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 8.31% year-over-year to $340.6 million; the TTM figure through Mar 2026 stood at $340.6 million (up 8.31% YoY), while the FY2025 annual figure was $388.9 million, up 21.33% from the prior year.
- Cash & Current Investments eased to $340.6 million in Q1 2026 per RYTM's latest filing, from $388.9 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $780.1 million in Q3 2025 and bottomed at $201.7 million in Q1 2024.
- Historically, Cash & Current Investments has averaged $325.9 million across 5 years, with a median of $299.6 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Current Investments sank 40.43% — and 2025, when it soared 161.02%.
- Rhythm Pharmaceuticals' Cash & Current Investments stood at $333.6 million in 2022, then fell by 17.22% to $276.2 million in 2023, then climbed by 16.07% to $320.6 million in 2024, then climbed by 21.33% to $388.9 million in 2025, then fell by 12.42% to $340.6 million in 2026.
- Business Quant data shows RYTM's Cash & Current Investments at $340.6 million in Q1 2026, $388.9 million in Q4 2025, and $780.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 330.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 330.90 Mn |
| Mar 31, 2026 | 340.63 Mn |
| Dec 31, 2025 | 388.95 Mn |
| Sep 30, 2025 | 780.07 Mn |
| Jun 30, 2025 | 291.56 Mn |
| Mar 31, 2025 | 314.49 Mn |
| Dec 31, 2024 | 320.57 Mn |
| Sep 30, 2024 | 298.85 Mn |
| Jun 30, 2024 | 319.59 Mn |
| Mar 31, 2024 | 201.66 Mn |
| Dec 31, 2023 | 276.17 Mn |
| Sep 30, 2023 | 299.59 Mn |
| Jun 30, 2023 | 253.93 Mn |
| Mar 31, 2023 | 294.91 Mn |
| Dec 31, 2022 | 333.62 Mn |
| Sep 30, 2022 | 348.12 Mn |
| Jun 30, 2022 | 235.92 Mn |
| Mar 31, 2022 | 241.29 Mn |
| Dec 31, 2021 | 295.18 Mn |
| Sep 30, 2021 | 328.68 Mn |